For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1186/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2014-2024

1. Pharma Leader Series: Top 25
Ophthalmic Drug Manufacturers
2014-2024
©notice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.

2. Contents
1.1. Executive Summary
Executive Summary
1.1 Leading Ophthalmic Drug Manufacturers: Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of this Report
1.5 Drugs Considered for this Report
1.6 Glossary of Terms in this Report
2.2. Introduction to the Ophthalmic Drugs Market
Introduction to the Ophthalmic Drugs Market
2.1 The Eye: An Overview of Its Structure and Function
2.2 The Global Burden of Eye Disease
2.3 Ophthalmic Drugs: Market Segmentation
2.4 Glaucoma: the ‘Silent Thief of Sight’
2.4.1 A Classification of Glaucoma
2.4.1.1 Primary Open-Angle Glaucoma
2.4.1.2 Acute Angle-Closure Glaucoma
2.4.1.3 Congenital Glaucoma
2.4.1.4 Secondary Glaucoma
2.4.1.5 Normal-Tension Glaucoma
2.4.1.6 Ocular Hypertension
2.4.2 Risk Factors for Glaucoma
2.4.3 Diagnosis of Glaucoma
2.4.4 Drug Treatment of Glaucoma
www.visiongain.com

3. Contents
2.4.5 Laser Treatment and Surgery for Glaucoma
2.5 Age-Related Macular Degeneration (AMD)
2.5.1 Dry (non-exudative) AMD
2.5.2 Wet (exudative) AMD
2.5.3 Risk Factors for AMD
2.5.4 Diagnosis of AMD
2.5.5 Treatment of AMD
2.6 Diabetic Retinopathy (DR)
2.6.1 Diagnosis of Diabetic Retinopathy
2.6.2 Treatment of Diabetic Retinopathy
2.7 Ocular Allergy and Allergic Conjunctivitis
2.7.1 Diagnosis of Ocular Allergy
2.7.2 Treatment of Ocular Allergy
2.8 Ocular Inflammatory Disease
2.8.1 Treatment of Ocular Inflammatory Disease
2.9 Eye Infections
2.9.1 Treatment of Eye Infections
2.10 Dry Eye Syndrome
2.10.1 Treatment of Dry Eye Syndrome
3.3. Ophthalmic Drugs: World Market 2014-2024
Ophthalmic Drugs: World Market 2014-2024
3.1 The World Ophthalmic Drugs Market in 2012 and 2013
3.2 World Ophthalmic Drugs Market: Sales Forecast 2014-2024
3.3 Leading Ophthalmic Drugs
www.visiongain.com

4. Contents
3.4 Leading Companies in the Ophthalmic Drugs Market
3.4.1 Top 25 Ophthalmic Drug Manufacturers 2014-2024
3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2014-2024
3.5.1 Glaucoma Drugs Market: Sales Forecast 2014-2024
3.5.2 Retinal Disorders Drugs Market: Sales Forecast 2014-2024
3.5.3 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2014-2024
3.5.4 Dry Eye Drugs Market: Sales Forecast 2014-2024
3.6 Changing Market Shares by Segment 2014-2024
3.7 World Ophthalmic Drugs Market: Drivers and Restraints
4.4. Leading US Ophthalmic Drug Manufacturers in 2012 and 2013
Leading US Ophthalmic Drug Manufacturers in 2012 and 2013
4.1 Allergan
4.1.1 Allergan: Ophthalmic Product Portfolio
4.1.1.1 Restasis: Sales Forecast 2014-2024
4.1.1.2 Lumigan and Ganfort: Sales Forecast 2014-2024
4.1.1.3 Refresh Brand Products: Sales Forecast 2014-2024
4.1.1.4 Alphagan/Alphagan P and Combigan: Sales Forecast 2014-2024
4.1.1.5 Acular: Sales Forecast 2014-2024
4.1.2 Allergan: Ophthalmic Product Pipeline
4.1.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for
Diabetic Macular Oedema
4.1.2.2 Novadur (Intravitreal Brimonidine Implant)
4.1.2.3 AGN 208397 (Beclomethasone Intravitreal Injection)
4.1.2.4 Anti-VEGF DARPins (VEGF Inhibitors)
www.visiongain.com

5. Contents
4.1.3 Allergan: Ophthalmic Revenue Forecast 2014-2024
4.1.4 Allergan: SWOT Analysis
4.2 Merck
4.2.1 Merck: Ophthalmic Product Portfolio
4.2.1.1 Trusopt: Sales Forecast 2014-2024
4.2.1.2 Zioptan: Sales Forecast 2014-2024
4.2.1.3 AzaSite (azithromycin)
4.2.2 Merck: Ophthalmic Product Pipeline
4.2.3 Merck: Revenue Forecast 2014-2024
4.2.4 Merck: Drivers and Restraints
4.3 Pfizer
4.3.1 Pfizer: Ophthalmic Product Portfolio
4.3.1.1 Xalatan/Xalacom: Sales Forecast 2014-2024
4.3.1.2 Macugen (Valeant/Pfizer)
4.3.2 Pfizer: Ophthalmic Product Pipeline
4.3.3 Pfizer: Revenue Forecast 2014-2024
4.3.4 Pfizer: SWOT Analysis
4.4 Regeneron
4.4.1 Regeneron: Ophthalmic Product Portfolio
4.4.1.1 Eylea: US Sales Forecast 2014-2024
4.4.2 Regeneron: Ophthalmic Product Pipeline
4.4.3 Regeneron: Revenue Forecast 2014-2024
4.4.4 FDA Approves Zaltrap (aflibercept)
4.4.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
www.visiongain.com

6. Contents
4.4.6 Regeneron: SWOT Analysis
5. Leading European Ophthalmic Drug Manufacturers in 2012 and 2013
5. Leading European Ophthalmic Drug Manufacturers in 2012 and 2013
5.1 Novartis (including Alcon)
5.1.1 Novartis: Ophthalmic Product Portfolio
5.1.1.1 Lucentis (ranibizumab)
5.1.1.2 Lucentis: Non-US Sales Forecast 2014-2024
5.1.1.3 Travatan/Travatan Z and DuoTrav: Sales Forecast 2014-2024
5.1.1.4 Vigamox: Sales Forecast 2014-2024
5.1.1.5 Azopt: Sales Forecast 2014-2024
5.1.1.6 Jetrea: Non-US Sales Forecast 2014-2024
5.1.2 Novartis: Ophthalmic Product Pipeline
5.1.2.1 Lucentis (ranibizumab) For Myopic Choroidal Neovascularisation
5.1.2.2 Finafloxacin (MerLion Pharmaceuticals/Novartis)
5.1.2.3 AKB-9778 (Aerpio Therapeutics)
5.1.2.4 AL-78898A (Complement Factor Inhibitor, Alcon)
5.1.3 Novartis: Revenue Forecast 2014-2024
5.1.4 Novartis: SWOT Analysis
5.2 Roche
5.2.1 Roche: Ophthalmic Product Portfolio
5.2.1.1 Lucentis: US Sales Forecast 2014-2024
5.2.1.2 Avastin: Sales Forecast 2014-2024
5.2.2 Roche: Ophthalmic Product Pipeline
5.2.2.1 Lampalizumab (RG7417)
www.visiongain.com

7. Contents
5.2.3 Roche: Revenue Forecast 2014-2024
5.2.4 Roche: SWOT Analysis
6.6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers in
Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers in
2012 and 2013
2012 and 2013
6.1 Santen
6.1.1 Santen: Ophthalmic Product Portfolio
6.1.1.1 Eylea: Japan Sales Forecast 2014-2024
6.1.1.2 Hyalein: Sales Forecast 2014-2024
6.1.1.3 Cosopt: Japan Sales Forecast 2014-2024
6.1.1.4 Tapros/Taflotan: Sales Forecast 2014-2024
6.1.1.5 Diquas: Sales Forecast 2014-2024
6.1.1.6 Cravit and Tarivid: Sales Forecast 2014-2024
6.1.2 Santen: Ophthalmic Product Pipeline
6.1.3 Santen: Revenue Forecast 2014-2024
6.1.4 Santen Acquires Novagali Pharma
6.1.5 Santen: SWOT Analysis
6.2 Senju
6.2.1 Senju: Ophthalmic Product Portfolio
6.2.2 Senju: Ophthalmic Product Pipeline
6.2.2.1 Y-39983 (SNJ-1656)
6.2.2.2 Difluprednate (SJE-2079)
6.2.3 Senju: Revenue Forecast 2014-2024
6.2.4 Senju: SWOT Analysis
6.3 Valeant
www.visiongain.com

8. Contents
6.3.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion?
6.3.2 Bausch and Lomb Had Acquired ISTA Pharmaceuticals
6.3.3 Valeant: Ophthalmic Product Portfolio
6.3.3.1 Macugen (Valeant/Pfizer): A Drug in Decline
6.3.4 Valeant: Ophthalmic Product Pipeline
6.3.4.1 Latanoprostene Bunod (BOL-303259-X)
6.4.3.2 Mapracorat (BOL-303242-X)
6.3.5 Valeant: Revenue Forecast 2014-2024
6.3.6 Valeant: SWOT Analysis
7.7. Emerging Ophthalmic Drug Manufacturers in 2012 and 2013
Emerging Ophthalmic Drug Manufacturers in 2012 and 2013
7.1 Pipeline and Other Companies, 2012-2013
7.2 Notable Terminated Drug Candidates
7.3 Abbott: Fenofibrate Approved in Australia for Diabetic Retinopathy
7.4 Acucela
7.5 Aerie Pharmaceuticals
7.6 Aerpio Therapeutics: Developing AKB-9778
7.7 Akorn
7.7.1 Cosopt/Cosopt PF: Sales Forecast 2014-2024
7.7.2 AzaSite: Sales Forecast 2014-2024
7.8 Alimera Sciences
7.8.1 Iluvien: Will It Gain FDA Approval?
7.8.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD
7.9 Altheos
www.visiongain.com

9. Contents
7.10 Amakem
7.11 Ampio Pharmaceuticals
7.12 Bayer
7.12.1 Eylea: non-US Sales Forecast 2014-2024
7.13 BioDiem
7.13.1 BDM-E: A High-Value Divestment?
7.14 Can-Fite BioPharma/OphthaliX
7.15 Chengdu Kanghong Pharmaceutical: Still Developing Conbercept?
7.16 Colby Pharmaceutical
7.16.1 CPC-551: A Potential Treatment for Geographic Atrophy in Dry AMD
7.17 Eleven Biotherapeutics
7.18 EyeGate Pharmaceuticals
7.19 Gene Signal
7.19.1 Aganirsen: Preventing Corneal Graft Rejection
7.19.2 GSK
7.19.3 Darapladib for Diabetic Macular Oedema
7.20 Icon Bioscience
7.21 Lpath
7.21.1 iSONEP: Antibodies Against Bioactive Lipids
7.22 MacuCLEAR
7.22.1 MC-1101: a Potential Therapy for Dry AMD
7.23 Neurotech
7.23.1 Renexus (NT-501) for Dry AMD
7.24 Omeros
www.visiongain.com

10. Contents
7.25 Ophthotech
7.25.1 Fovista: A Strong Competitor for the AMD Market
7.25.2 ARC1905: Complement C5 Inhibitor
7.25.3 Has Volociximab Been Terminated?
7.26 Otsuka Pharmaceutical
7.27 OXiGENE: Developing Zybrestat for Wet AMD
7.28 RXi Pharmaceuticals: Will Bevasiranib Resume Development?
7.29 Shire
7.29.1 Jerini Ophthalmic’s JSM6427 and JPE-1375 Terminated?
7.29.2 Lifitegrast (SHP606) for Dry Eye
7.29.3 Premiplex (SHP607): Preventing Retinopathy of Prematurity
7.30 Sirnaomics: Acurita (STP601) Still in Preclinical Development?
7.31 ThromboGenics
7.31.1 Jetrea (ocriplasmin)
7.31.1.1 Jetrea: US Sales Forecast 2014-2024
7.31.2 TB-403: Anti-Placental Growth Factor
8.8. Qualitative Analysis of the Ophthalmic Drugs Market 2014-2024
Qualitative Analysis of the Ophthalmic Drugs Market 2014-2024
8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market
8.1.1 Rivalry Among Competitors [Medium]
8.1.2 Threat of New Entrants [Low]
8.1.3 Power of Suppliers [Low]
8.1.4 Power of Buyers [Medium]
8.1.5 Threat of Substitutes [Medium]
www.visiongain.com

11. Contents
9.9. Research Interviews
Research Interviews
9.1 Interview with Professor David T. Shima, PhD, Institute of Ophthalmology, University
College London, UK
9.1.1 On the Role of VEGF in Retinal Disorders
9.1.2 On Candidate Molecule E10030
9.1.3 On Candidate Molecule JSM 6427
9.1.4 On New Sustained Release Formulations
9.1.5 On Delta-Notch Signalling
9.1.6 Potential Clinical Crossovers Between Ophthalmology and Oncology
9.1.7 Commercial and Clinical Possibilities in the Ophthalmology Market
9.1.8 On the Possibilities of Research into the Endothelial Fenestra
9.2 Expert Interview 2: Authority from a Company in the Industry (Views Provided
Anonymously)
9.2.1 Key Unmet Needs
9.2.2 Challenges Facing the Ophthalmic Sector
9.2.3 On Current Ophthalmic Treatments and Their Effectiveness
9.2.4 On Opportunities in the Ophthalmic Sector
9.3 Interview with Sean Ainsworth, CEO and Founder of RetroSense Therapeutics, Ann Arbor,
Michigan, USA
9.3.1 The Optogenetic Approach to Vision Restoration
9.3.2 Choosing Disease Targets and Delivery Vectors
9.3.3 The Regulatory Picture
9.3.4 Gene Therapies in AMD and Other Ophthalmic Therapeutic Areas
www.visiongain.com

12. Contents
9.3.5 The Next Ten Years for Gene Therapy
9.4 Interview with Philip G. Ralston, Jr., CEO of MacuCLEAR, Plano, Texas, USA
9.4.1 MC-1101: Identifying and Treating Chiou Syndrome
9.4.2 Preventing Dry AMD Progression
9.4.3 Treating the Root Cause of Dry AMD
9.4.4 Phase 3: Endpoints and Prospects for MC-1101
9.5 Interview with Dr Michael Stewart, Associate Professor, Mayo Clinic, Jacksonville, Florida,
USA
9.5.1 The Impact of Eylea
9.5.2 The Comparative Dosing Schedules of Eylea and Lucentis
9.5.3 Patient Transitioning to Eylea: Salvage Switching
9.5.4 Avastin after the CATT Study
9.5.5 Prospects for Eylea in Other Indications and Combinations
9.5.6 Future Possibilities in Wet AMD Treatment
10. Conclusions
10. Conclusions
10.1 Ophthalmic Pharmaceuticals: A Growing Niche Market
10.2 The World Ophthalmic Drugs Market in 2012 and 2013
10.2.1 Leading Ophthalmic Drugs Market Segments
10.2.2 Leading Ophthalmic Drugs
10.2.3 Leading Ophthalmic Drug Manufacturers
10.3 World Ophthalmic Drugs Market Forecast 2014-2024
10.4 The Future of the Ophthalmic Drugs Market?
10.4.1 Increasing Revenue Concentration among Specialist Companies
10.4.2 The Rise of Generics
www.visiongain.com

13. Contents
10.4.3 Small Companies Can Have a Big Impact
10.4.4 What Will Succeed in the Ophthalmic Drugs Market?
List of Tables
Table 1.1 Currency Exchange Rates, 2012
Table 2.1 ICD-10 Classification of Visual Impairment, 2010
Table 2.2 Drug Treatments for Glaucoma, 2013
Table 2.3 Drug Treatments for AMD, 2013
Table 2.4 Drug Treatments for Ocular Allergy, 2013
Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2013
Table 2.6 Selected Drug Treatments for Eye Infections, 2013
Table 3.1 World Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment,
2012-2013
Table 3.2 World Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 20122024
Table 3.3 Top 10 Ophthalmic Drugs: Revenue ($m), 2012-2013
Table 3.4 Top 10 Ophthalmic Drug Manufacturers: Net Revenue ($m), Ophthalmic Drugs
Revenue ($m), Market Share (%), 2012-2013
Table 3.5 Top 25 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Leading
Pipeline Products, 2013
Table 3.6 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by
Segment, 2012-2018
Table 3.7 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by
Segment, 2018-2024
Table 3.8 Glaucoma Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
www.visiongain.com

14. Contents
Table 3.9 Retinal Disorders Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 20122024
Table 3.10 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenues ($m), AGR
(%), CAGR (%), 2012-2024
Table 3.11 Dry Eye Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 3.12 Market Shares (%) of the Ophthalmic Drugs Market by Segment, 2012, 2018 and
2024
Table 4.1 Allergan: Overview, 2012-2013
Table 4.2 Allergan: Ophthalmic Drug Products, 2013
Table 4.3 Allergan: Restasis Revenue ($m), AGR (%), CAGR(%), 2002-2012
Table 4.4 Allergan: Restasis Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.5 Allergan: Lumigan Revenue ($m), AGR (%), CAGR(%), 2000-2012
Table 4.6 Allergan: Lumigan and Ganfort Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.7 Allergan: Refresh Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.8 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%), CAGR(%),
2012-2024
Table 4.9 Allergan: Acular Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.10 Allergan: Revenues ($m) and Revenue Shares (%) by Region, 2012
Table 4.11 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.12 Allergan: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Table 4.13 Merck: Overview, 2012-2013
Table 4.14 Merck: Trusopt Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.15 Merck: Zioptan Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.16 Merck: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.17 Pfizer: Overview, 2012-2013
www.visiongain.com

15. Contents
Table 4.18 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.19 Pfizer: Macugen Revenue ($m), AGR (%), CAGR(%), 2004-2012
Table 4.20 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.21 Pfizer: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Table 4.22 Regeneron: Overview, 2012-2013
Table 4.23 Regeneron: Eylea Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.24 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 4.25 Regeneron: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Table 5.1 Novartis: Overview, 2012-2013
Table 5.2 Novartis: Lucentis Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.3 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%), CAGR(%), 20122024
Table 5.4 Novartis: Vigamox Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.5 Novartis: Azopt Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.6 Novartis: Jetrea Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.7 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.8 Novartis: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Table 5.9 Roche: Overview, 2012-2013
Table 5.10 Roche: Lucentis Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.11 Roche: Avastin Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.12 Roche: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 5.13 Roche: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Table 6.1 Santen: Overview, 2012-2013
Table 6.2 Santen: Revenue ($m) and Revenue Share (%) by Segment, 2012-2013
Table 6.3 Santen: Eylea Revenue ($m), AGR (%), CAGR(%), 2012-2024
www.visiongain.com

16. Contents
Table 6.4 Santen: Hyalein Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.5 Santen: Cosopt Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.6 Santen: Tapros/Taflotan Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.7 Santen: Diquas Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.8 Santen: Cravit and Tarivid Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.9 Santen: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.10 Santen: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Table 6.11 Senju: Overview, 2012-2013
Table 6.12 Senju: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.13 Senju: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Table 6.14 Valeant: Overview, 2012-2013
Table 6.15 Valeant: Selected Products Revenue ($m), 2010-2012
Table 6.16 Valeant: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 6.17 Valeant: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Table 7.1 Akorn: Cosopt and Cosopt PF Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 7.2 Akorn: AzaSite Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 7.3 Bayer: Eylea Revenue ($m), AGR (%), CAGR(%), 2012-2024
Table 7.4 ThromboGenics: Jetrea Revenue ($m), AGR (%), CAGR(%), 2012-2024
www.visiongain.com

17. Contents
List of Figures
Figure 2.1 Structure of the Human Eye
Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2012
Figure 2.3 Global Causes of Visual Impairment (% of cases), 2012
Figure 2.4 Classification of Glaucoma, 2013
Figure 3.1 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2012
Figure 3.2 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2013
Figure 3.3 World Ophthalmic Drugs Market Forecast: Revenue ($m), 2012-2024
Figure 3.4 Top 10 Ophthalmic Drug Manufacturers: Market Share (%), 2013
Figure 3.5 Glaucoma Drugs Market Forecast: Revenues ($m), 2012-2024
Figure 3.6 Retinal Disorders Drugs Market Forecast: Revenues ($m), 2012-2024
Figure 3.7 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenues ($m), 20122024
Figure 3.8 Dry Eye Drugs Market Forecast: Revenues ($m), 2012-2024
Figure 3.9 World Ophthalmic Drugs Market: Market Shares (%) by Segment, 2018
Figure 3.10 World Ophthalmic Drugs Market: Market Shares (%) by Segment, 2024
Figure 3.11 World Ophthalmic Drugs Market: Drivers and Restraints, 2014-2024
Figure 4.1 Allergan: Restasis Revenue ($m), 2002-2012
Figure 4.2 Allergan: Restasis Revenue ($m), 2012-2024
Figure 4.3 Allergan: Lumigan Revenue ($m), 2000-2012
Figure 4.4 Allergan: Lumigan and Ganfort Revenue ($m), 2012-2024
Figure 4.5 Allergan: Refresh Revenue ($m), 2012-2024
Figure 4.6 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), 2012-2024
www.visiongain.com

18. Contents
Figure 4.7 Allergan: Acular Revenue ($m), 2012-2024
Figure 4.8 Allergan: Revenue Shares (%) by Region, 2012
Figure 4.9 Allergan: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 4.10 Allergan: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 4.11 Merck: Trusopt Revenue ($m), 2012-2024
Figure 4.12 Merck: Zioptan Revenue ($m), 2012-2024
Figure 4.13 Merck: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 4.14 Merck: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 4.15 Merck: Drivers and Restraints, 2014-2024
Figure 4.16 Pfizer: Xalatan/Xalacom Revenue ($m), 2012-2024
Figure 4.17 Pfizer: Macugen Revenue ($m), 2004-2012
Figure 4.18 Pfizer: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 4.19 Pfizer: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 4.20 Regeneron: Eylea Revenue ($m), 2012-2024
Figure 4.21 Regeneron: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 4.22 Regeneron: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 5.1 Novartis: Lucentis Revenue ($m), 2012-2024
Figure 5.2 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), 2012-2024
Figure 5.3 Novartis: Vigamox Revenue ($m), 2012-2024
Figure 5.4 Novartis: Azopt Revenue ($m), 2012-2024
Figure 5.5 Novartis: Jetrea Revenue ($m), 2012-2024
Figure 5.6 Novartis: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 5.7 Novartis: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 5.8 Roche: Lucentis Revenue ($m), 2012-2024
www.visiongain.com

19. Contents
Figure 5.9 Roche: Avastin Revenue ($m), 2012-2024
Figure 5.10 Roche: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 5.11 Roche: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 6.1 Santen: Ophthalmic Drugs Revenue ($m) by Segment, 2012
Figure 6.2 Santen: Eylea Revenue ($m), 2012-2024
Figure 6.3 Santen: Hyalein Revenue ($m), 2012-2024
Figure 6.4 Santen: Cosopt Revenue ($m), 2012-2024
Figure 6.5 Santen: Tapros/Taflotan Revenue ($m), 2012-2024
Figure 6.6 Santen: Diquas Revenue ($m), 2012-2024
Figure 6.7 Santen: Cravit and Tarivid Revenue ($m), 2012-2024
Figure 6.8 Santen: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 6.9 Santen: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 6.10 Senju: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 6.11 Senju: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 6.12 Valeant: Ophthalmic Drugs Revenue ($m), 2012-2024
Figure 6.13 Valeant: Ophthalmic Drugs Market Share (%), 2012-2024
Figure 7.1 Akorn: Cosopt and Cosopt PF Revenue ($m), 2012-2024
Figure 7.2 Akorn: AzaSite Revenue ($m), 2012-2024
Figure 7.3 Alimera Sciences: Ophthalmic Drug Pipeline Progress, 2013
Figure 7.4 Bayer: Eylea Revenue ($m), 2012-2024
Figure 7.5 Gene Signal: Ophthalmic Drug Pipeline Progress, 2013
Figure 7.6 Neurotech: Ophthalmic Drug Pipeline Progress, 2013
Figure 7.7 Ophthotech: Ophthalmic Drug Pipeline Progress, 2013
Figure 7.8 Shire: Ophthalmic Drug Pipeline Progress, 2013
www.visiongain.com

20. Contents
Figure 7.9 ThromboGenics: Jetrea Revenue ($m), 2012-2024
Figure 8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market, 2014-2024
Figure 10.1 World Ophthalmic Drugs Market: Revenues ($m) by Segment, 2013
Figure 10.2 World Ophthalmic Drugs Market: Revenues ($bn), 2012-2024
Figure 10.3 Leading Ophthalmic Drugs Manufactuters: Revenues ($m), 2012-2024
Companies Listed
Abbott Laboratories (Abbott)
Abbvie
Acucela
Advanced Vision Research (acquired by Akorn)
Aerie Pharmaceuticals
Aerpio Therapeutics
Akorn Pharmaceuticals
Alcon (subsidiary of Novartis)
Alimera Sciences
Allergan
Allergro Ophthalmics
Altheos
Amakem
Ampio Pharma
Asahi Glass
AstraZeneca
Aton Pharma (acquired by Valeant)
www.visiongain.com

21. Contents
Banyu Pharmaceutical (part of Merck)
Bausch and Lomb (subsidiary of Valeant)
Bayer
Bayer Yakuhin (Japanese subsidiary of Bayer)
BioDiem
Biogen Idec
BioInvent International
Biovail Corporation (part of Valeant)
Bristol-Myers Squibb
Can-Fite BioPharma
Chengdu Kanghong Pharmaceutical
Chiron Corportation (part of Novartis)
Chugai Pharmaceutical (part of Roche)
CIBA VISION (part of Novartis)
Ciba-Geigy (part of Novartis)
Colby Pharmaceutical Company (Colby)
CoMentis
Daiichi Sankyo
Eleven Biotherapeutics
Eli Lilly and Company (Lilly)
EyeGate Pharmaceuticals
Eyetech Inc. / Eyetech Pharmaceuticals (acquired by Valeant)
Fougera Pharmaceuticals (acquired by Novartis)
Gene Signal
www.visiongain.com

22. Contents
Genentech (subsidiary of Roche)
Genzyme (subsidiary of Sanofi)
Gilead Sciences
GSK
ICN Pharmaceuticals (original Valeant company)
Icon Bioscience
Inamed Corporation (subsidiary of Allergan)
InSite Vision
Inspire Pharmaceuticals (acquired by Merck)
ISTA Pharmaceuticals (part of Valeant)
Jerini AG
Jerini Ophthalmic (part of Jerini AG)
Johnson & Johnson
Kestrel Ophthalmics
Kyorin Pharmaceutical
Kyowa Hakko Kirin
LEO Pharma
Lpath
MacuCLEAR
MacuSIGHT, Inc.
MAP Pharmaceuticals (acquired by Allergan)
Meda
Medicis Corporation (acquired by Valeant)
Merck & Co. (Merck)
www.visiongain.com

23. Contents
MerLion Pharmaceuticals
MSD K.K. (part of Merck)
Mylan Pharmaceuticals
Mystic Pharmaceuticals
Neurotech
NicOx
Nippon Boehringer Ingelheim (subsidiary of Boehringer Ingelheim)
NovaBay Pharmaceuticals
Novagali Pharma (acquired by Santen)
Novartis
Novo (subsidiary of Novo Nordisk)
Novo Nordisk
Oakwood Laboratories
OcuSciences
Omeros
Onyx Pharmaceuticals
OphthaliX (part-owned by Can-Fite BioPharma)
Ophthotech
OPKO Health
Ora
OSI Pharmaceuticals
Othera Pharmaceuticals (acquired by Colby)
Otsuka Pharmaceutical
Oxford BioMedica
www.visiongain.com

24. Contents
OXiGENE
Parke-Davis (subsidiary of Pfizer)
PDL BioPharma
Pfizer
Pharmacia (acquired by Pfizer)
Potentia Pharmaceuticals
Premacure
Procter & Gamble
pSivida
Quark Pharmaceuticals
Reckitt Benckiser
Regeneron
RetroSense Therapeutics
ReVision Therapeutics
Roche
RXi Pharmaceuticals
Sandoz (part of Novartis)
Sanofi
Santen Pharmaceutical Co. (Santen)
SARcode Bioscience
Schering-Plough (part of Merck)
Senju
Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd. (subsidiary of Senju)
Senju USA Inc. (subsidiary of Senju)
www.visiongain.com

25. Contents
Shire
Sirion Therapeutics
Sirna Therapeutics
Sirnaomics
SkinMedica (subsidiary of Allergan)
Spark Therapeutics
Symphony ViDA
Takeda Pharmaceutical
Teva
The Patent Board
ThromboGenics
Upjohn (acquired by Pfizer through Pharmacia)
Valeant Pharmaceuticals
Ventana Medical Systems (acquired by Roche)
Warburg Pincus LLC
Warner-Lambert (acquired by Pfizer)
Watson Pharmaceuticals
Wyeth Pharmaceuticals (part of Pfizer)
www.visiongain.com

26. Contents
Other Organisations Mentioned in This Report
A*STAR Institute for Infocomm Research (Singapore)
American Academy of Ophthalmology (AAO)
American Diabetes Association
American Society of Retina Specialists (ASRS)
Association for Research in Vision and Ophthalmology (ARVO)
Council of Europe
Emory University
European Medicines Agency (EMA)
Foundation Fighting Blindness (FFB) (US)
Health Canada
Institute of Experimental Medicine (Russia)
Institute of Ocular Pharmacology, Texas A&M (US)
Institute of Ophthalmology, University College London (UK)
Intellectual Property Appellate Board (India)
International Diabetes Federation
Internet Archive
Japan Patent Office (JPO)
Mayo Clinic
Ministry of Health, Labour and Welfare (MHLW) (Japan)
Monash University
National Eye Institute (NEI) (US)
National Health Service (NHS) (UK)
National Institute for Health and Care Excellence (NICE) (UK)
www.visiongain.com

27. Contents
NHS Scotland
Novartis Institutes for BioMedical Research (NIBR) (part of Novartis)
Novartis Venture Funds (NVF) (part of Novartis)
Ophthalmology External Research Unit (part of Pfizer)
Ophthrisi (GSK research unit)
Rinat (Pfizer research unit)
Texas Emerging Technology Fund
Therapeutic Goods Administration (TGA) (Australia)
Tokyo University of Science
United States Food and Drug Administration (FDA)
University of Florida
University of Kentucky
University of Melbourne
University of Michigan
US Preventive Services Task Force (USPSTF)
US Securities and Exchange Commission (SEC)
World Health Organization (WHO)
www.visiongain.com

28. Pharma Leader Series: Top 25 Ophthalmic
Drug Manufacturers 2014-2024
4.1.1.5 Acular: Sales Forecast 2014-2024
Acular (ketorolac tromethamine, Allergan) is a topical NSAID eyedrop solution, indicated in the
relief of ocular itching due to seasonal allergic conjunctivitis and post-operative ocular
inflammation. First launched in the Netherlands and Canada in 1992, it is now available in several
other countries worldwide, including the UK, Germany and the US. New forms, Acular PF and
Acular LS, have since received FDA approval and are also available in the US market.
Visiongain estimates that sales of Acular had declined to $60m in 2012. We predict that sales will
continue to decline further, reaching $33m in 2018 for a CAGR of -9.3% over 2012-2018. The US
patent for ketorolac tromethamine expired in the fourth quarter of 2009 and generic versions of
Acular are available. Sales will continue to fall from 2018 to 2024, reaching $26m in 2024 (Table
4.9 and Figure 4.7). This represents a CAGR of -4.2% over 2018-2024 and an overall CAGR of
-6.8% over 2012-2024.
Table 4.9 Allergan: Acular Revenue ($m), AGR (%), CAGR(%), 2012-2024
Acular ($m)
Annual Growth Rate (%)
CAGR (%, 2012-2018 and
2018-2024)
CAGR (%, 2012-2024)
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
60
54
48
44
39
36
33
31
30
28
27
26
26
-10.0 -10.0 -10.0 -10.0 -8.0 -8.0 -6.0 -5.0 -5.0 -3.0 -3.0 -3.0
-9.3
-4.2
-6.8
Source: visiongain 2013
Figure 4.7 Allergan: Acular Revenue ($m), 2012-2024
70
60
60
Revenue ($m)
50
54
48
40
44
39
36
33
30
31
30
28
27
26
26
20
10
0
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Year
Source: visiongain 2013
www.visiongain.com
Page 84

29. Pharma Leader Series: Top 25 Ophthalmic
Drug Manufacturers 2014-2024
•
Warner-Lambert, acquired in 2000 for around $90bn. Warner-Lambert itself had become a
major pharmaceutical player through mergers and acquisitions, having joined with ParkeDavis during the 1970s.
•
Pharmacia and its subsidiary Upjohn, acquired in April 2003 for $60bn.
•
Wyeth Pharmaceuticals, acquired in January 2009 for $68bn. This acquisition gave Pfizer
access to additional ophthalmic products.
The company is perhaps best known for its blockbuster drug Lipitor (atorvastatin), which lost patent
protection in November 2011. In July 2011, Pfizer announced that it intended to focus on its core
pharmaceutical business in the future and planned to divest its animal health and nutrition
divisions. In April 2012, Nestlé acquired the company’s infant nutrition business and in January
2013, Pfizer’s Animal Health business became a separate company called Zoetis. Table 4.17
presents an overview of Pfizer.
Table 4.17 Pfizer: Overview, 2012-2013
Ranking in 2013 (2012)
Company
Notable Subsidiaries
Business Areas
Established
Headquarters
FY 2012 Revenue ($m)
FY2012 Ophthalmic
Drugs Revenue ($m)
Leading Ophthalmic
Drugs
Market Share, 2012 (%)
Market Share, 2024 (%)
7 (7)
Pfizer, Inc.
Wyeth (2009)
Pharmaceuticals, nutritionals, vaccines,
consumer health
1849
New York City, New York, US
58,896
812
Xalatan/Xalacom, Macugen
4.5
0.7
Source: Company reports; visiongain 2013
4.3.1 Pfizer: Ophthalmic Product Portfolio
Pfizer currently markets three ophthalmic products: Xalatan (latanoprost) and Xalacom
(latanoprost/timolol) for glaucoma and Macugen (pegaptanib) for wet AMD. Both Xalatan/Xalacom
and Macugen face generic competition. Generic latanoprost was launched in Japan in May 2010
and launches in other major markets followed. Xalatan lost exclusivity in the US in March 2011 and
the company lost exclusivity for Xalatan and Xalacom in 15 major European markets in January
2012.
www.visiongain.com
Page 99

30. Pharma Leader Series: Top 25 Ophthalmic
Drug Manufacturers 2014-2024
Table 6.10 Santen: Ophthalmic Drugs Market SWOT Analysis, 2012-2024
Strengths
Strong ophthalmic pipeline covering all major
segments of the ophthalmic drugs market
Strong presence in Asia-Pacific markets,
especially Japan where it is market leader
Weaknesses
Vulnerable to generic competition for several
products such as Hyalein and Cravit
Opportunities
Threats
Competition in domestic and international
markets
Failure of pipeline candidates in clinical trials
Expansion into US and European markets
Greater penetration into the Chinese market
Limited presence in the US and Europe
Source: visiongain 2013
Santen has a well established history in the manufacture of ophthalmic drugs that dates back to
over 120 years in the market. It remains the market leader in Japan in 2013. Santen has focused
much of its marketing activity for ophthalmics on the domestic market and has entered copromotion agreements for some of its products in other markets. In 2010, for example, Santen
entered into a co-promotion agreement with Banyu Pharmaceutical Co., Ltd. (currently MSD K.K.)
regarding the glaucoma and ocular hypertension treatment Cosopt Combination Ophthalmic
Solution. A number of pipeline products are also being developed in collaboration with partners in
the US and elsewhere.
The company has continued to grow and develop especially in the Asian markets with strong
penetration throughout Asia including Korea and Hong Kong. Santen already enjoys a leading
position in China’s prescription ophthalmic pharmaceutical market where the company began
direct marketing its products in 2009 to further enhance its presence in that market. Moreover,
Santen has also filed an application for manufacturing and marketing approval in China and has
completed construction of a production plant in Suzhou, China.
The company has a global vision and aims to become an international player in this sector. To
make this happen, Santen will need to improve its presence in the US and European markets. In
Europe, the acquisition of Novagali Pharma (now Santen S.A.S.) has helped to achieve this as well
as bringing one marketed product and four pipeline candidates to the company. In the US, it was
reported that in March 2013 Santen made substantial changes to the management structure of its
US subsidiary, Santen Inc, supporting the idea that Santen is increasingly focusing on business
activities in the US market.
Santen’s pipeline is very strong compared to many of the industry leaders discussed in this report,
with candidates in all major segments of the ophthalmic drugs market. Particularly notable,
perhaps, are the recent launches of Diquas in Japan and South Korea, considering that Allergan’s
www.visiongain.com
Page 154